Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
2022studies shown
Showing 1,576-1,600 of 2,022
CompletedNCT05532683

Feasibility Trial of a Lifestyle Intervention for CHR-P

This study exists to see whether psychoeducation, a guided learning and support program, is workable and worth testing more broadly. Researchers are trying to understand whether psychoeducation, a guided learning and support program, can improve sleep, daily rhythms, and longer-term stability.

SchizophreniaOtherFrom 13 Years to 17 Years
Countries
United States
Sponsor
University of California, Los Angeles
Condition
Schizophrenia
CompletedNCT06518330

Psychosis Associated With Methylphenidate in Children and Adolescents

This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 5 Years to 17 Years
Countries
France
Sponsor
University Hospital, Caen
Condition
Schizophrenia
RecruitingNCT06505564

VR-based Avatar Therapy for Treatment of Auditory Hallucinations

This study exists to see whether a therapy or guided support program can make care clearer and more responsive. Researchers are trying to understand whether a therapy or guided support program can give earlier or clearer feedback during care.

SchizophreniaOtherOver 18 Years
Countries
Hungary, Poland, Spain
Sponsor
Semmelweis University
Condition
Schizophrenia
RecruitingNCT06505668

Effect of Atenolol Versus Ivabradine on HRV in TRS Patients on Clozapine With Tachycardia: A Randomised Control Trial.

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
India
Sponsor
All India Institute of Medical Sciences, Bhubaneswar
Condition
Schizophrenia
CompletedNCT05911529

Motivational Interviewing for Patients With Acute Psychosis

This study exists to see whether cognitive behavioural therapy, a structured talking treatment, is workable and worth testing more broadly. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Switzerland
Sponsor
Psychiatric University Hospital, Zurich
Condition
Schizophrenia
Not Yet RecruitingNCT06501339

Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia

This study exists to compare options and see whether a therapy or guided support program offers something meaningfully different. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
Global
Sponsor
All India Institute of Medical Sciences, Bhubaneswar
Condition
Schizophrenia
RecruitingNCT06494124

Efficacy and Safety of tACS vs tDCS in Schizophrenia

This study exists to see whether this type of care can make care clearer and more responsive. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
India
Sponsor
All India Institute of Medical Sciences, Bhubaneswar
Condition
Schizophrenia
CompletedNCT02969382

A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia

This study exists to understand whether a medication treatment is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
Hungary, Romania, Russian Federation, Ukraine, United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT02970929

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

This study exists to understand how the medication Safety holds up over time after the earliest research stage. Researchers are trying to understand how people respond to the medication Safety in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
Hungary, Romania, Russian Federation, Ukraine, United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
RecruitingNCT06482918

Cognitive Remediation in Schizophrenia: Efficacy and Role of Neuroplasticity in "Top-down" and "Bottom-up" Mechanisms

This study exists to understand how a therapy or guided support program holds up over time after the earliest research stage. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 59 Years
Countries
Chile
Sponsor
University of Chile
Condition
Schizophrenia
RecruitingNCT06482554

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

This study exists to see whether this type of care can make care clearer and more responsive. Researchers are trying to understand whether this type of care can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Louisiana State University Health Sciences Center Shreveport
Condition
Schizophrenia
CompletedNCT04239612

Fitforlife- Exercise in Care of Psychosis

This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Sweden
Sponsor
Karolinska Institutet
Condition
Schizophrenia
CompletedNCT04072354

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

This study exists to understand whether a digital app or remote support tool is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 13 Years to 65 Years
Countries
Bulgaria, Colombia, Russian Federation, Serbia, Ukraine, United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT01940159

A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT01972711

Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics

This study exists to explore whether blood tests and biological markers could improve care and understanding. Researchers are trying to understand what blood tests and biological markers can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 45 Years
Countries
United Kingdom
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT04865835

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

This study exists to see whether acceptance and commitment therapy, a talking treatment, can play a useful role in care. Researchers are trying to understand whether acceptance and commitment therapy, a talking treatment, can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT04369391

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what a digital app or remote support tool could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT05463770

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT05402111

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what a digital app or remote support tool could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT05848700

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what a digital app or remote support tool could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT05542264

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT01994473

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

This study exists to better understand the safety of blood tests and biological markers and how manageable it feels in practice. Researchers are trying to understand how people respond to blood tests and biological markers in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT04092686

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

This study exists to understand whether a digital app or remote support tool is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Bulgaria, Croatia, Latvia, Russian Federation, Serbia, Ukraine, United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Schizophrenia | Clinical Trials | HopeStage Research